Vitals & Signals
The FDA is quietly rewriting the fundamental contract of clinical AI regulation — moving from a pre-market permission slip to a post-market surveillance regime — and every founder, investor, and clinician in this industry needs to understand what that means before the framework lands.
6 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af Vitals & Signals-fællesskabet!